Merck (NYSE:MRK) said on Monday that its late-stage study, testing Winrevair in adults with moderate to high risk pulmonary ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Gen Z grads are slamming degrees as worthless—but Fortune 500 boss, Doina Ionescu, says her MBA was the best investment ...

Merck launches AI-powered search, offering patients fast, trusted answers from its widely used medical manuals and resources.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

CareTrust, Merck, and Allete have rewarded shareholders for years and recently announced dividend increases. These companies ... Shareholders of Merck would probably like to forget the past six ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

The First Lady, Lordina Mahama, has commended Merck Foundation for strengthening the healthcare system in Ghana and Africa ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...